statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 Cadrenal Therapeutics to Participate in Noble Capital Markets...

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total...

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD  Get Free Report) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 21,900 shares, a...

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Up 204.2% in March

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update PR Newswire PONTE VEDRA, Fla., March 11, 2024 PONTEVEDRA, Fla...

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference...

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of...

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions Cadrenal Therapeutics Highlights...

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 Cadrenal Therapeutics to Participate in a Fireside Chat at the...

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference Cadrenal Therapeutics to Present at the Biotech Showcase on January...

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Volume	81,336.00
52-Wk High	$3.14
52-Wk Low	$0.36

CVKD Cadrenal Therapeutics, Inc.

About

Feed

News

Fundamentals